NTI 1309
Alternative Names: 64Cu-LNTH-1363S; LNTH-1363S; NTI-1309Latest Information Update: 05 Jun 2024
At a glance
- Originator Noria Therapeutics
- Developer Lantheus Holdings
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Gastrointestinal cancer; Sarcoma
Most Recent Events
- 31 May 2024 Phase-I/II clinical trials in Gastrointestinal cancer (Diagnosis) (unspecified route) (NCT06298916) (Lantheus pipeline, June 2024)
- 31 May 2024 Phase-I/II clinical trials in Sarcoma (Diagnosis) (unspecified route) (NCT06298916) (Lantheus pipeline, June 2024)
- 31 May 2024 Phase-I/II clinical trials in Sarcoma (Diagnosis, Metastatic disease) (unspecified route) (NCT06298916) (Lantheus pipeline, June 2024)